Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Abstract Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. In this study, we evaluated the long-term efficacy, safety, and tolerability of monthly and quart...

Full description

Bibliographic Details
Main Authors: Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Yoel Kessler, Lindsay Janka, Hans-Christoph Diener
Format: Article
Language:English
Published: BMC 2021-07-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Calcitonin gene-related peptide
CGRP
Long-term safety
Long-term efficacy
Online Access:https://doi.org/10.1186/s10194-021-01279-7

Internet

https://doi.org/10.1186/s10194-021-01279-7

Similar Items